Biomedical subjects

Jan Bucerius

Publications and source records attributed to Jan Bucerius.

25 records · Page 2Linked to original sources

PubMed2003

Mitral valve repair in patients with end stage cardiomyopathy: who benefits?

OBJECTIVE: Patients with end stage cardiomyopathy frequently present with additional severe mitral regurgitation. We analyzed the outcome of mitral valve reconstruction in this high risk patient group. METHODS: Sixty-six patients with significant mitral regurgitation and an ejection fraction (EF) below 30% (dilated cardiomyopathy=53, ischemic cardiomyopathy (ICM)=13) were retrospectively evaluated from 07/96 and 02/02. All received annuloplasty ring implantation and additional repair (n=4) if required. Mean follow-up was 28+/-18 months. RESULTS: Mitral valve repair (MVR) was technically feasible in all patients. Intraoperative transesophageal echocardiography (TEE) revealed none (n=60) or only trivial (n=6) residual mitral regurgitation. Thirty day mortality was 6.1%. Actuarial survival after 1 and 5 years was 86+/-4 and 66+/-8%, respectively. During follow-up seven patients were transplanted due to lack of clinical improvement after 10+/-7 months (range 1-23). Echocardiography revealed a significant improvement in EF (25+/-10.5% pre-op, 34+/-15% post-op) and a slight decrease in left ventricular end-diastolic diameter (69+/-10 mm pre-op, 67+/-13 mm follow up). Patients were in NYHA functional -class 3 (median) preoperatively and in class 2 at long term-follow-up. Gender, left ventricular enddiastolic diameter, preoperative ejection fraction or type of surgical approach (sternotomy, right lateral minithoracotomy) had no significant influence on patient outcome. Patients with ICM or patients older than 60 years showed an increased risk for clinical events both early post-operatively and at long-term follow-up. CONCLUSION: MVR can be performed with low perioperative morbidity and mortality even in patients with advanced heart failure, modifying selection criteria for potential candidates may further improve long term outcome.

Adult↗

PubMed2002

Endoscopic internal thoracic artery dissection leads to significant reduction of pain after minimally invasive direct coronary artery bypass graft surgery.

BACKGROUND: The aim of this study was to evaluate postoperative pain levels after endoscopic versus conventional internal thoracic artery (ITA) dissection for minimally invasive direct coronary artery bypass graft surgery (MIDCABG) surgery. Results were compared with pain levels associated with conventional cardiac bypass operations through a median sternotomy. METHODS: Of 190 patients included in this prospective study, 24 patients had endoscopic ITA takedown (MIDCABG-endo) using the da Vinci telemanipulator followed by a manual coronary anastomosis through a left minithoracotomy. A conventional MIDCABG operation (MIDCABG-conv) was performed in 73 patients with ITA preparation under direct vision. Postoperative pain levels after conventional CABG through a median sternotomy (CABG-conv, n = 93) served as controls. A standarized questionnaire including visual analog scale (VAS) was used for prospective pain assessment from POD 1 to 7. RESULTS: Pain levels (VAS) declined in all groups from POD 1 to 7. Overall pain levels were significantly lower in the MIDCABG-endo group as compared with MIDCABG-conv and CABG-conv groups, respectively (p < 0.001, general linear model). There was no significant difference between the MIDCABG-conv and CABG-conv (p = not significant, general linear model) groups. Furthermore, patients after MIDCABG-endo required fewer nonsteroidal anti-inflammatory drugs and opioid medications, postoperatively. CONCLUSIONS: An endoscopic ITA takedown in MIDCABG surgery leads to significantly reduced postoperative pain levels possibly because of less rib retraction.

Aged↗

PubMed2002

Minimal access aortic valve replacement: effects on morbidity and resource utilization.

BACKGROUND: The aim of this study was to compare outcomes in patients undergoing minimal access versus conventional aortic valve replacement (AVR). METHODS: We reviewed prospectively gathered data on all patients who were undergoing first-time AVR, with or without replacement of the ascending aorta, over a 1-year period at our institution. RESULTS: A total of 176 patients underwent minimal access and 258 underwent conventional AVR. The conventional group was older, had more incidence of diabetes, and more aortic stenosis (all p < 0.05). Eight minimal access AVR patients (2%) required conversion to a complete sternotomy. Minimal access AVR patients had longer aortic crossclamp times than conventional AVR patients (60 +/- 22 vs 55 +/- 23 minutes, p = 0.03) but similar CPB times (93 +/- 38 vs 88 +/- 42 minutes, p = 0.20). Postoperative creatine kinase-MB levels were similar for the two groups. Total postoperative blood loss was significantly lower in the minimal access group, and these patients received less red blood cell and fresh frozen plasma transfusions. Minimal access AVR patients were less likely to have postoperative respiratory failure (3% vs 10%); they had shorter intensive care unit stays (3.7 +/- 5.4 vs 4.5 +/- 5.6 days) and shorter hospital stays (10 +/- 6 vs 12 +/- 7 days, all p < 0.05). Mortality was lower in patients undergoing minimal access surgery (3% vs 9%, p = 0.008) by univariate analysis. Multivariate predictors of mortality were age, hypertension, and CPB time. CONCLUSIONS: Although patient selection may have influenced some of the observed differences between our patient groups, minimal access surgery appears to be associated with decreased morbidity and resource use when compared to conventional AVR.

Aortic Valve↗

PubMed2002

Experimental evaluation and early clinical results of a new low-profile bileaflet aortic valve.

We performed an experimental and clinical evaluation of a new low-profile bileaflet aortic valve (Regent, St. Jude Medical Inc., St. Paul, MN, U.S.A.). Common valve sizes were experimentally tested for leakage volume, pressure drop, and transvalvular hemodynamics using a pulse duplicator. Thirty patients (mean age 60 +/- 7 years, predominant valve stenosis n = 25) received the Regent prosthesis for initial clinical evaluation. In vitro evaluation revealed equivalent leakage volumes, larger performance indices (0.552 versus 0.513), and lower pressure drops in comparison to SJM hemodynamic plus valve controls. Clinically, 21 mm (n = 9), 23 mm (n = 12), and 25 mm (n = 9) valves were implanted with no significant perioperative complications. Echocardiography revealed low transvalvular flow velocities (2.2 +/- 0.4 m/s) and low pressure gradients (20 +/- 6 mm Hg) postoperatively and at 6 months follow-up. In vitro testing and early clinical results are promising; however, long-term performance has to be proven.

Aged↗

PubMed2002

Hemodynamic evaluation of stentless mitral valve replacement.

The purpose of this study was to evaluate the perioperative and postoperative hemodynamic function of recently introduced stentless mitral valves (SMVs). Forty-two selected patients who had received the SMV since 1997 had preoperative, postoperative, and follow-up transthoracic echocardiographic (TTE) examinations. Transesophageal echocardiography (TEE) was applied routinely during the operation as well as postoperatively if indicated. Adequate SMV function was seen in all patients perioperatively. Echocardiographic prediction of valve size and of papillary muscle distances was correct in 37 of 42 patients. Transvalvular blood flow velocities were 1.6 +/- 0.2 m/s postoperatively versus 1.8 +/- 0.3 m/s at 1 year and 1.7 +/- 0.3 m/s at 3-year follow-up. Mean transvalvular gradients were 4.3 +/- 1.6, 3.8 +/- 1.9, and 4.7 +/- 1.1 mm Hg, respectively. TEE and TTE are extremely useful to assist SMV implantation as well as for regular follow-up evaluation. The hemodynamic function after SMV implantation with preservation of the annulo-ventricular continuity is promising.

Aged↗

PubMed2002

Five years of less invasive mitral valve surgery: from experimental to routine approach.

BACKGROUND: In the last five years, mitral valve surgery has changed fundamentally. This study reviews our experience in less invasive mitral valve surgery (LIMS) during that time. METHODS: LIMS was performed in 449 patients (age 59 +/- 14 years, 237 female) via a right lateral minithoracotomy. The operations included 42 "redo" procedures. After initially experiencing a high number of complications, we have modified and simplified the procedure. After using the Port- Access? Technique (PAT) in the earlier stages of our series, in the last 226 patients the aorta was clamped directly using the transthoracic clamping (Chitwood) technique (TTC). In our most recent cases, PAT was only employed in redo procedures. In 336 patients, the procedure was completed with robotic assistance, and in 23 of these we used the da Vinci telemanipulation system. RESULTS: The mitral valve was repaired in 327 patients and replaced in 122 patients. In 100 patients, additional surgical procedures (TVR n = 13, ASD closure n = 16, left atrial ablation n = 65, left atrial reduction plasty n = 6) were performed. Bypass and clamp time, including times for both additional and redo procedures, were 124 +/- 44 min. and 65 +/- 29 min. in the overall series. Complications, which were mainly neurological, were fewer in the TTC group than in the PAT group (n = 4 vs. n = 17; p <0.04). Hospital mortality was 3.1% and 5.2%, respectively, for the two groups. There were no additional costs associated with using the TTC technique compared to conventional procedures. Mean survival rate was 96.3% at a mean follow-up of 727 +/- 451 days (95% CI, 677 to 779). CONCLUSIONS: Less invasive mitral valve surgery enables the patient to avoid the surgical trauma associated with sternotomy. It has developed into a reliable technique with reproducible results for primary, redo, and additional procedures. LIMS has become the standard approach for mitral valve operations at our institution.

Cardiac Surgical Procedures↗

PubMedDate not supplied

Temporary extracorporeal membrane oxygenation in patients with refractory postoperative cardiogenic shock--a single center experience.

BACKGROUND: Approximately 1% of patients require temporary circulatory support due to refractory cardiogenic shock following cardiac surgery. Such patients are at very high risk for subsequent morbidity and mortality. We evaluated the results of temporary extracorporeal membrane oxygenation (ECMO) support in patients with postcardiotomy cardiogenic shock. METHODS: From November 1997 to February 2000, 7900 patients underwent cardiac surgery in our institution. Ninety-five patients (1.2%) (CABG, n = 63; AVR, n = 16; CABG and AVR, n = 8; other procedures, n = 8) required temporary postoperative ECMO support. ECMO implantation was performed via the femoral vessels or via the right atrium and ascending aorta. Intraaortic balloon counterpulsation was employed in all patients. RESULTS: Mean duration of ECMO support was 2.8 +/- 2.1 days. Forty-five patients (47%) were successfully weaned from ECMO. Of these, 28 patients were discharged from hospital 35.8 +/- 20.8 days post-ECMO support. Overall hospital mortality for all ECMO patients was considerable at 71%. Mortality rate in the combined CABG and AVR group was 100% (P < 0.05 versus the other surgical groups). ECMO support was complicated by renal failure in 64% of patients, bleeding requiring mediastinal reexploration in 62%, ischemia of the lower limbs in 16%, cerebral edema in 6%, and cerebral hemorrhage in 3%. CONCLUSIONS: ECMO is a suitable technique for short-term treatment of refractory postoperative low cardiac output. Mortality rates are comparable to other cardiac assist devices, with approximately 30% of patients able to be discharged from hospital.

Aged↗